Introduction
Acute myeloid leukemia (AML) can occur at any stage of life yet the mutations that cause AML differ between childhood and adulthood, especially when one compares young children to adults (Chaudhury et al., 2015) . For example, MLL translocations and GATA1 mutations are common in infant and early childhood AML but rare in adult AML (Andersson et al., 2015; Horton et al., 2013; Pine et al., 2007) . Mutations in FLT3, NPM1, DNMT3A, TET2 and IDH1 are all common in adult AML but rare in infant and early childhood AML (Cancer Genome Atlas Research Network, 2013; Ho et al., 2011; Liang et al., 2013; Zwaan et al., 2003) . The genetic differences between pediatric and adult AML are not absolute, but they reflect a more general phenomenon in leukemia biologyleukemias in infants, young children, older children and adults have different genetic and epigenetic landscapes, different mechanisms of transformation and different clinical courses (Downing and Shannon, 2002) . Efforts to interpret AML genomes and translate the information into useful therapies will need to account for the influences of age and developmental context on leukemia cell biology. This will require a better understanding of how normal developmental programs shape the process of leukemogenesis.
The mutations that cause AML are thought to accrue first in pre-leukemic hematopoietic stem cells (HSCs) or committed hematopoietic progenitor cells (HPCs) (Jan et al., 2012; Welch et al., 2012) , and several properties of these cells change between fetal and adult stages of life: (1) Fetal HSCs divide frequently and retain their self-renewal capacity through cumulative division cycles (Pietras and Passegué, 2013) . In contrast, adult HSCs are usually quiescent, and self-renewal capacity declines with cumulative divisions (Foudi et al., 2009; Pietras and Passegué, 2013; Wilson et al., 2008) . (2) Fetal and adult HSCs have distinct self-renewal mechanisms. For example, Sox17 is required for fetal, but not adult, HSC self-renewal (Kim et al., 2007) . Etv6, Ash1l, Mll and Pten are all required for adult, but not fetal, HSC self-renewal (Hock et al., 2004; Jones et al., 2015; Jude et al., 2007; Magee et al., 2012) . (3) Fetal and adult HSCs give rise to committed progenitors with distinct epigenetic landscapes (Huang et al., 2016; Xu et al., 2012) and distinct lineage biases (Benz et al., 2012; Copley et al., 2013; Yuan et al., 2012) . These observations raise the question of whether mutations can have age-specific effects on gene expression, self-renewal, differentiation and ultimately leukemogenesis. If so, competence for transformation may be a heterochronic property of HSCs and HPCs, and this may explain why pediatric and adult leukemias have different mutations.
The FLT3 Internal Tandem Duplication (FLT3 ITD ) is an example of an AML driver mutation that occurs more commonly in adults than in young children (30-40% of adult AML, 5-10% of AML in children <10 years old, <1% of infant AML) (Meshinchi et al., 2006) . FLT3 ITD encodes a constitutively active tyrosine kinase receptor that has been shown to activate the STAT5, MAP-kinase (MAPK), PI3-kinase (PI3K), STAT3 and NF-kB signal transduction pathways in various contexts (Choudhary et al., 2007; Gerloff et al., 2015; Radomska et al., 2006) . Mice with a targeted Flt3 ITD mutation develop myeloproliferative neoplasms (MPN) (Lee et al., 2007; Li et al., 2008) , and several other mutations (e.g. Npm1, Tet2 and Runx1 mutations) cooperate with Flt3 ITD to drive AML in mice much as in humans (Mead et al., 2013; Mupo et al., 2013; Rau et al., 2014; Shih et al., 2015) . In the absence of cooperating mutations, Flt3 ITD drives adult HSCs into cycle and depletes the HSC pool (Chu et al., 2012) . This may explain why FLT3 ITD mutations occur late in the clonal evolution of human AML -adult HSCs must first acquire mutations that preserve (or ectopically establish) selfrenewal capacity in pre-leukemic progenitors-but it also raises the question of why fetal/neonatal HSCs, which have an inherently high self-renewal capacity (He et al., 2009) , do not give rise to FLT3 ITD positive AML more often than is observed.
To better understand how developmental context shapes myeloid leukemogenesis, we characterized the effects of Flt3 ITD on HSC self-renewal, myelopoiesis, signal transduction and gene expression at several stages of pre-and post-natal development. Flt3 ITD did not cause HSC depletion or myeloid progenitor expansion until after birth. This was true even in the presence of a cooperating Runx1 loss-of-function mutation. Figure 1A) , consistent with prior studies (Buza-Vidas et al., 2011) , but its expression did not change with age in either cell population ( Figure 1A ). Flow cytometry confirmed that the FLT3 protein is expressed in both fetal and adult progenitors ( Figure 1B ). Since Flt3 ITD has previously been shown to deplete adult HSCs (Chu et al., 2012) , we tested whether the mutation has a similar effect on fetal HSC numbers. We measured HSC numbers in 8-10 week old adult bone marrow and E14.5 fetal livers from wild type, Flt3 ITD/+ and Flt3 ITD/ITD mice.
Adult Flt3 ITD/+ mice had~50% fewer HSCs than wild type littermates, consistent with prior studies, and Flt3 ITD/ITD mice had a near-complete loss of phenotypic HSCs ( Figure 1C ). HSC depletion in the bone marrow was not accompanied by extramedullary expansion of HSCs in the spleen ( Figure 1E ), in contrast to other leukemogenic mutations (e.g. Pten deletion) that cause depletion of bone marrow HSCs but marked expansion of the spleen HSC population (Magee et al., 2012; Porter et al., 2016) . Unlike adult mice, Flt3 ITD/+ and Flt3 ITD/ITD fetal mice had similar numbers of HSCs as wild type littermates ( Figure 1D ). The Flt3 ITD mutation therefore depletes adult, but not fetal HSCs.
We next tested whether fetal Flt3 ITD/ITD HSCs are functionally impaired. We performed limiting dilution transplantation assays with either 8-10 week old adult bone marrow cells (600,000, 100,000, 50,000 or 10,000 CD45.2 donor cells competed with 300,000 CD45.1 adult bone marrow cells) or E14.5 fetal liver cells (100,000, 50,000 or 10,000 CD45.2 donor cells competed with 300,000 CD45.1 adult bone marrow cells). Two independent experiments were performed, and fetal and adult donor cells were transplanted at the same time in each experiment. Multi-lineage reconstitution was assessed every 4 weeks for 16 weeks following the transplants, and functional HSC frequencies were calculated by Extreme Limiting Dilution Analysis (Hu and Smyth, 2009) . Adult Flt3 ITD/ITD bone marrow had significantly fewer functional HSCs than adult wild type bone marrow (p<0.00001, Figure 1F ). In contrast, wild type and Flt3 ITD/ITD fetal livers had similar HSC frequencies ( Figure 1G ).
Our findings raised the question of whether fetal Flt3 ITD/ITD HSCs can mature and become depleted after transplantation into adult recipient mice. To test this, we measured donor HSC chimerism in primary recipients of 100,000 wild type and Flt3 ITD/ITD fetal liver cells (from Figure 1G ).
Donor
Flt3 ITD/ITD HSCs were significantly depleted in primary recipient mice, but wild type competitor HSCs were not ( Figure 1H ). Overall donor bone marrow chimerism was not significantly different between recipients of wild type and Flt3 ITD/ITD fetal liver cells ( Figure 1I ). Secondary transplants confirmed depletion of Flt3 ITD/ITD HSCs in the marrow of primary recipients ( Figure 1J ,K). Thus, fetal 
Flt3
ITD causes HSC depletion and myeloid progenitor expansion by two weeks after birth in mice
We next sought to define the age at which Flt3 ITD begins to deplete HSCs and expand myeloid progenitor populations. We measured HSCs, HPCs and granulocyte-monocyte progenitor (GMP) numbers at E14.5, E16.5, post-natal day (P)0 and P14. Flt3 ITD/+ and Flt3 ITD/ITD mice had normal HSC numbers at all ages prior to birth (Figure 2A) . HSC depletion was evident at P14 in both the bone marrow and the spleen, though not to the extent observed in adult bone marrow ( Figure 2B ). We observed a modest increase in Flt3 ITD/+ and Flt3 ITD/ITD HPCs and GMPs at P0 ( Figure 2C ,E), and this phenotype became more severe, particularly in Flt3 ITD/ITD mice, by P14 ( Figure 2D, (Schnittger et al., 2011) , and Runx1 deletions synergize with
ITD to cause AML in mice (Mead et al., 2013) . For the purposes of these studies, we focused on mono-allelic Runx1 deletions because bi-allelic deletions severely depleted phenotypic HSCs irrespective of the Flt3 genotype (data not shown). These effects were likely due to previously described, Runx1-dependent changes in CD48 expression (Cai et al., 2011 Figure 3C,D) . In contrast, all four genotypes of mice had similar HSC frequencies at P0 ( Figure 3B ), and Runx1 heterozygosity increased HSC frequency at E14.5 irrespective of the Flt3 genotype ( Figure 3A ). HPCs and GMPs were markedly expanded in P14 and P21 Flt3 ITD/+; Runx1 D/+ mice ( Figure 3G ,H,K,L). These populations were only modestly expanded in compound mutant mice at P0 ( Figure 3F ,J), and they were not expanded at all at E14.5 ( Figure 3E ,I). We next tested whether compound Flt3 ITD and Runx1 mutations had age-specific effects on HSC/ HPC function. We transplanted 100,000 P0 liver cells or P21 bone marrow cells from control or Runx1 D/+ P21 donor cells had multi-lineage donor chimerism (>0.5% CD45.2 + myeloid and lymphoid cells) ( Figure 3O ). In contrast, all recipients of control and Flt3 ITD/+; Runx1 D/+ P0 donor cells had multi-lineage donor chimerism ( Figure 3O ). These differences were evident even when we focused specifically on myeloid chimerism ( Figure 3N ,P), so they were not simply a reflection of altered lineage biases in the Flt3 ITD/+; Runx1 D/+ progenitors. Altogether, these data show that Flt3 ITD has developmental context-specific effects on HSC depletion, myeloid progenitor expansion and repopulating activity, even when paired with a cooperating Runx1 mutation. (O,P) Percentage of recipients with multi-lineage (O) or myeloid (P) donor reconstitution at four weeks after transplantation. In all panels, error bars indicate standard deviations. For A-L, n = 8-18 biological replicates per genotype and age. For (M-P), n = 14-15 recipients from three independent donors. Statistical significance was determined with a one-way ANOVA followed by Holm-Sidak's post-hoc test for multiple comparisons (*p<0.05; **p<0.01; ***p<0.001), or # p<0.0001 by the Fisher exact probability test. (Choudhary et al., 2007; Radomska et al., 2006) . However, the data suggest that these pathways are not coupled -STAT5 is phosphorylated in fetal progenitors without concurrent MAPK pathway activation. This raises the question of whether each pathway has unique functions downstream of FLT3 ITD .
MAPK pathway inhibition has little to no effect on Flt3 ITD -driven HSC depletion, HPC expansion and GMP expansion
We used the MEK inhibitor PD0325901 to test whether MAPK pathway inhibition could prevent HSC depletion and HPC/GMP expansion in Flt3 ITD mice. We administered vehicle or PD0325901 to 6-week-old wild type and Flt3 ITD/+ mice (5 mg/kg per day for 10 days). This regimen effectively inhibited ERK1/2 phosphorylation in HPCs without affecting STAT5 phosphorylation ( Figure 5 -figure supplement 1). PD0325901-treated wild type mice had significantly more phenotypic HSCs and HPCs than vehicle treated controls ( Figure 5A ,B). However, PD0325901 had no effect on HSC numbers, HPC numbers or GMP frequencies in Flt3 ITD/+ mice ( Figure 5A -C). This suggests that sustained MAPK pathway signaling is not required for HSC depletion, HPC expansion and GMP expansion in Flt3 ITD/+ adult mice.
We next tested whether PD0325901 could prevent the onset of the HSC depletion, HPC expansion and GMP expansion phenotypes if it was given shortly after birth. We treated nursing mothers of wild type, Flt3 ITD/+ and Flt3 ITD/ITD neonates with PD0325901 (5 mg/kg per day) beginning at P1.
While this regimen has previously been shown to rescue MAPK pathway-dependent developmental abnormalities in Nf1 mutant neonates (Wang et al., 2012) , it did not prevent HSC depletion or HPC expansion in Flt3 ITD mutant neonates ( Figure 5D ,E), and it only partially rescued GMP expansion ( Figure 5F ). Altogether, the data suggest that the MAPK pathway has only a minor role, if any, in causing these phenotypes. Temporal changes in MAPK pathway regulation are unlikely to account for the different effects of FLT3 ITD on fetal and adult progenitors. Figure 5D ). Similar results were observed when we deleted a single Stat5a/b with Vav1-cre. Only one Stat5a/b allele was deleted in these analyses because bi-allelic deletion impairs fetal erythropoiesis (Zhu et al., 2008) . Nevertheless, Flt3 ITD/+ ; Stat5a/b f/+ ; Vav1-Cre mice had fewer HSCs, more
HPCs, more GMPs and larger spleens than control or Flt3 ITD/+ littermates at 8-10 weeks after birth ( Figure 6E-H) .
The data reveal an unanticipated function for STAT5 in pre-leukemic, Flt3 ITD -mutant progenitors.
They suggest that STAT5 helps to maintain Flt3 ITD -mutant HSCs in an uncommitted state and that it antagonizes Flt3 ITD -driven expansion of more committed myeloid progenitor populations. Thus,
FLT3
ITD may simultaneously potentiate self-renewal and myeloid commitment programs via STAT5-dependent and STAT5-independent pathways, respectively ( Figure 6I ). The changes in HSC and HPC frequencies in Flt3 ITD ; Stat5a/b compound mutant mice raise the question of whether FLT3 ITD has STAT5-dependent and STAT5-independent effects on gene expression, and whether transcriptional changes are developmental context-specific. To answer these questions we performed two independent experiments to characterize global changes in gene expression ( Figure 7A ). We analyzed the data from each experiment independently, and we merged the data to identify a list of genes that were significantly, differentially expressed in FLT3 ITD progenitors in both experiments. In experiment 1, we identified 254 annotated coding genes that were differentially expressed between wild type and Flt3 ITD/+ HPCs at one or more time points (Figure 7 -source data 1; adjusted p<0.05; fold change ! 2). We did not identify any genes that met these stringent filtering criteria in HSCs, though statistically significant changes in gene expression were observed when specific target genes (from the HPC list) were individually interrogated (p<0.05, Figure 7 -source data 1). The differences between HSCs and HPCs may simply reflect differences in Flt3 expression ( Figure 1A ), though it is also possible that HSCs with the strongest transcriptional responses to FLT3 ITD were not captured in our microarray assays because they differentiated. Of the 254 genes that were differentially expressed in experiment 1, 58 unique genes were also differentially expressed between wild type and Flt3 ITD/+ HPCs in experiment 2 ( Figure 7B and Figure 7 -figure supplement 1). Thirty-three genes were expressed at higher levels in Flt3 ITD HPCs relative to wild type HPCs, and 25 genes were expressed at lower levels ( Figure 7B ). Of these, 35 normalized when Stat5a/b was deleted, but 23 did not. FLT3 ITD therefore has both STAT5-dependent and STAT5-independent effects on gene expression, and these effects are more pronounced in HPCs as compared to HSCs. We tested whether FLT3 ITD activates self-renewal-and commitment-related transcriptional programs via STAT5-dependent and STAT5-independent mechanisms, respectively, as predicted by our phenotypic assays ( Figure 6 ). We generated self-renewal-related and commitment-related gene sets by comparing wild type HSCs and HPCs using the data collected in experiment 1 (Figure 7 -source data 2). We then used Gene Set Enrichment Analysis (GSEA) to compare wild type, Flt3 ITD/+ and Flt3 ITD/+ ; Stat5 D/D HPCs using data collected in experiment 2 (Subramanian et al., 2005) . Selfrenewal-related genes were enriched in Flt3 ITD/+ HPCs, and commitment-related genes were enriched in wild type HPCs ( Figure 7C ). This suggests that the FLT3 ITD protein can activate selfrenewal mechanisms in otherwise non-self-renewing HPCs. Remarkably, these effects were strongly reversed when Stat5a/b was deleted ( Figure 7C) Figure 7D ) (Ivanova et al., 2002) . These findings are consistent with a model in which FLT3 ITD signals via STAT5 to ectopically activate self-renewal programs in HPCs, and it simultaneously promotes myeloid commitment via STAT5-independent mechanisms. In all panels, error bars indicate standard deviation. Statistical significance was determined with a one-way ANOVA followed by Holm-Sidak's post-hoc test for multiple comparisons. *p<0.05; **p<0.01; ***p<0.001. DOI: 10.7554/eLife.18882.010
The following figure supplement is available for figure 6: figure. (C) Self-renewal and commitment-related gene sets were generated by identifying genes that were more highly expressed (>5 fold, adj. p<0.05) Figure 7 continued on next page
To better understand the STAT5-independent mechanisms that promote myeloid commitment, we performed GSEA on HPCs were generally associated with increased inflammatory cytokine signaling ( Figure 7E ). This finding is intriguing because several prior studies have linked inflammatory cytokine signaling to loss of adult HSC self-renewal capacity and myeloid differentiation (Baldridge et al., 2010; Essers et al., 2009; Pietras et al., 2016) . Of note, we did not observe changes in STAT1, STAT3 or AKT phosphorylation in ITD has the capacity to activate functionally relevant signal transduction pathways, such as STAT5, during both pre-and post-natal stages of development (Figure 4 ), yet HSC and HPC phenotypes were only observed after birth. This raises the question of whether pre-and post-natal progenitors have distinct transcriptional responses to FLT3 ITD . We evaluated FLT3 ITD target gene expression in HPCs at E14.5, P0, P14 and adulthood ( Figure 8A ). We found that differences between wild type and Flt3 ITD/+ HPCs were more evident at P14 and adulthood than at E14.5 or P0
( Figure 8A and Figure 8 -figure supplement 1). This was true for both STAT5-dependent targets, e.g. Socs2, and STAT5-independent targets, e.g. Ctsg ( Figure 8B) . Thus, fetal, neonatal and adult hematopoietic progenitors have distinct transcriptional responses to FLT3 ITD signaling.
To better understand when HSCs and HPCs transition from fetal to adult transcriptional programs, we analyzed gene expression in wild type cells from experiment 1. We identified 2627 unique genes (from 3005 different probes) that exhibited significant changes in gene expression in HSCs between E14.5 and adulthood. Of the 228 most differentially expressed transcripts (from the top 250 probes), all followed a consistent trend toward increasing (109 genes) or decreasing (119 genes) expression with increasing age, and most were differentially expressed in both HSCs and HPCs ( Figure 8C, Figure 8 -source data 1). Among these genes were several that encode transcription factors and RNA binding proteins that are known to regulate HSC self-renewal, including Lin28b, Esr1, Hmga2 and Egr1 (Figure 8C,D) . Principal component analysis and Euclidean distance measurements showed that P14 HSCs more closely resembled adult HSCs than fetal HSCs, and P0 HSCs more closely resembled fetal HSCs ( Figure 8E ). Similar associations were observed for HPCs (Figure 8-figure supplement 2) . The data show that HSCs and HPCs begin transitioning from fetal to adult transcriptional programs by P14, even before they achieve quiescence (Bowie et al., 2006) . Furthermore, the data suggest that HSCs and HPCs become competent to express (or repress) FLT3
ITD target genes as they transition from fetal to adult transcriptional programs. (Shih et al., 2015) . We tested whether Flt3 ITD and Runx1 mutations have similar cooperative effects on transcription and whether the effects are age-specific. We evaluated gene expression in (1) wild type, (2) Runx1 D/+ , (3) Flt3 ITD/+ and (4) Flt3 ITD/+ ; Runx1 D/+ HPCs at P0 and P14.
At P14, we identified 191 genes that were significantly differentially expressed between wild type and Flt3 ITD/+ ; Runx1 D/+ HPCs (adj. p<0.05; fold change ! 3). At P0 only eight genes met these criteria, seven of which overlapped with the P14 gene list ( Figure 9A and Figure 9 -source data 1). GSEA showed significant overlap between genes that were differentially expressed in Figure 9B ). This suggests that FLT3 ITD can cooperate with diverse mutations to induce a conserved set of target genes. We used hierarchical clustering to better visualize differences in gene expression at P0 and P14. This approach did show some differences between wild type and Flt3 ITD/+ ; Runx1 D/+ HPCs at P0
( Figure 9C ), but much greater differences were observed at P14 for most target genes ( Figure 9C,  D) . Of the 25 most differentially expressed genes in P14 Flt3 ITD/+ ; Runx1 D/+ HPCs, only three -Nov, Bhlhe40 and Mboat2 -were induced equally at both P0 and P14 ( Figure 9D , Figure 9 -source data 1). The remaining genes showed only a partial change in expression at P0 (e.g. Socs2) or no change in expression (e.g. Adgre1, Dusp6, Gem, Postn) ( Figure 9D ). GSEA also showed differences in the transcriptional programs of P0 and P14 Flt3 ITD/+ ; Runx1 D/+ HPCs. Several Gene Ontology and Oncogenic Signature gene sets were enriched in P14 Flt3 ITD/+ ; Runx1 D/+ HPCs relative to wild type controls, the most significant of which included genes that are negatively regulated by mTOR (Majumder et al., 2004) , genes that inhibit apoptosis (Gene Ontology) and c-myc targets (Bild et al., 2006 ) ( Figure 9E ). These gene sets were not significantly enriched in P0 HSCs with the exception of the anti-apoptotic gene set, which was paradoxically enriched in wild type HPCs relative to Flt3 ITD/+ ; Runx1 D/+ ( Figure 9E) . Altogether, the data show that cooperating Flt3 ITD and Runx1 mutations -and likely other cooperating mutations -have developmental context-specific effects on gene expression.
Discussion
Our data offer a potential explanation for why FLT3 ITD mutations are rare in infants and young children with AML. The mutant FLT3 ITD protein hyper-activates STAT5 in hematopoietic progenitors during both fetal and adult stages of development, yet its effects on transcription are realized selectively in adult progenitors. Even cooperative interactions between Flt3 ITD and Runx1 heterozygous mutations are blunted during fetal and perinatal stages. Thus, FLT3 ITD mutations may occur disproportionately in older children and adults with AML because they are less able to activate key effectors of leukemogenesis during earlier stages of life.
Flt3
ITD has distinct STAT5-dependent and STAT5-independent effects on self-renewal and myeloid commitment, respectively
In the course of these studies, we discovered that Stat5a/b deletion exacerbates, rather than rescues, the HSC depletion, HPC/GMP expansion and MPN phenotypes of Flt3 ITD/+ mice. Furthermore, 
FLT3
ITD ectopically activated STAT5-dependent self-renewal programs in HPCs (Figure 7) . These unanticipated findings suggest that FLT3 ITD activates both STAT5-dependent and STAT5-independent signal transduction pathways and that these pathways have opposing effects on self-renewal and myeloid commitment. In this model, STAT5-independent myeloid commitment programs outweigh STAT5-dependent self-renewal programs in the Flt3 ITD mutant bone marrow so the HSC pool becomes depleted ( Figure 6I and Figure 7 ). Stat5a/b deletion can shift the balance further in favor of differentiation, though cooperating mutations may ultimately allow STAT5-dependent selfrenewal programs to predominate in transformed AML cells. The STAT5-independent pathways that antagonize HSC self-renewal and promote myeloid progenitor expansion remain unclear. While the MAPK pathway was hyper-activated in postnatal Flt3 ITD/+ HSCs and HPCs, MEK inhibition did not prevent, or even reduce, HSC depletion or HPC expansion in these mice ( Figure 5 ). Other candidate pathways, including STAT3 and PI3K, were not activated by FLT3 ITD ( Figure 4A ). It is possible that low levels of signal transduction via these pathways were undetectable by Western blot but nevertheless functionally important. It is also possible that an un-interrogated pathway, such as NF-kB or CDK1 (Gerloff et al., 2015; Radomska et al., 2012) Developmental programming, re-programming and the origins of pediatric and adult malignancies
Heterochronic genes have been implicated in cancer pathogenesis (Shyh-Chang and Daley, 2013) . For example, hepatoblastomas, Wilm's tumors and most neuroblastomas present early in life, and they often express the oncofetal proteins LIN28 or LIN28B at high levels to help maintain the primitive differentiation states of their respective anlagen (Diskin et al., 2012; Molenaar et al., 2012; Nguyen et al., 2014; Urbach et al., 2014) . Adult hepatocellular carcinomas, germ cell tumors and ovarian carcinomas often ectopically activate LIN28 or LIN28B to restore oncofetal programs (Viswanathan et al., 2009) . MLL-rearranged leukemias have similarly been shown to express embryonic stem cell-related genes (Somervaille et al., 2009) , and BRAF V600E driven melanoma was recently shown to arise from melanocytes that first de-differentiate into primitive neural crest progenitors (Kaufman et al., 2016) . In each of these cases, it is easy to appreciate why maintaining or restoring a primitive cell identity might accelerate transformation-fetal cells can proliferate rapidly without differentiating or senescing. However, it is then curious as to why pediatric malignancies are relatively uncommon. Does this simply reflect greater fidelity of the genome at early ages, or are other factors at work? Our data suggest that the transcriptional regulatory programs of fetal progenitors may, in fact, be protective against some mechanisms of transformation. Fetal and adult progenitors interpret that determine when and how individual mutations are competent to transform. If we can understand how normal developmental programs interact with genetic mutations to cause malignancies, it may be possible to target these interactions therapeutically.
Materials and methods

Mouse strains
The Flt3 , 1995) mouse strains have all been previously described and were obtained from The Jackson Laboratory (Bar Harbor, ME). These lines were all on a pure C57BL/6 background. Expression of Mx1-Cre was induced by three intraperitoneal injections of pIpC (GE Life Sciences, Pittsburgh, PA; 10 mg/dose) over five days beginning six weeks after birth. PD0325901 (Cayman Chemicals, Ann Arbor, MI) was suspended in 0.5% hydroxypropylmethylcellulose vehicle (Sigma) and administered by oral gavage as described in the text. All mice were housed in the Department for Comparative Medicine at Washington University. All animal procedures were approved by the Washington University Committees on the Use and Care of Animals.
Isolation of HSCs and flow cytometry
Bone marrow cells were obtained by flushing the long bones (tibias and femurs) or by crushing long bones, pelvic bones and vertebrae with a mortar and pestle in calcium and magnesium-free Hank's buffered salt solution (HBSS), supplemented with 2% heat inactivated bovine serum (Gibco, Carlsbad, CA). Splenocytes were obtained by macerating spleens with frosted slides. Single cell suspensions were filtered through a 40 um cell strainer (Fisher, Houston, TX). The cells were then stained for 20 min with fluorescently conjugated antibodies, washed with HBSS + 2% bovine serum and resuspended for analysis. Cell counts were measured by hemocytometer. The following antibodies were used for flow cytometry, all were from Biolegend (San Diego, CA) except as indicated: CD150 (TC15-12F12.2), CD48 (HM48-1), Sca1 (D7), c-Kit (2B8), Ter119 (Ter-119), CD3 (17A2), CD11b (M1/70), Gr-1 (RB6-8C5), B220 (RA3-6B2), CD8a (53-6.7), CD34 (eBioscience/Affymetrix, Santa Clara, CA, RAM34), CD2 (RM2-5), CD45.1 (A20), CD45. 
Limiting dilution long-term repopulation assays
Eight to ten week old C57BL/6Ka-Thy-1.2 (CD45.1) recipient mice were given two doses of 550 rad delivered at least 3 hr apart. Donor fetal liver or bone marrow cells were mixed with competitor bone marrow cells at the doses indicated in the text and injected via the retroorbital sinus. To assess donor chimerism, peripheral blood was obtained from the submandibular veins of recipient mice at the indicated times after transplantation. Blood was subjected to ammonium-chloride lysis of the red blood cells and leukocytes were stained with antibodies to CD45.2, CD45.1, B220, CD3, CD11b and Gr-1 to assess multilineage engraftment. Functional HSC frequencies were calculated and compared by using Extreme Limiting Dilution Analysis (Hu and Smyth, 2009) . For secondary transplants, mice were injected with 3 million cells from the bone marrow of primary recipient mice.
Quantitative RT-PCR
RNA was isolated from HSCs with RNAeasy micro plus columns (Qiagen) and converted to cDNA with Superscript III reverse transcriptase (Lifetech, Carlsbad, CA). Quantitative RT-PCR assays were performed with Taqman Gene Expression Assays specific to mouse Flt3 and b-actin (Lifetech). Analysis was performed with a Mx3005P qPCR system (Agilent, Wilmington, DE). Samples were normalized based on b-actin expression.
Western blots
Twenty-five thousand HSC/MPPs, HPCs or GMPs were double sorted into Trichloracetic acid (TCA), and the volume was adjusted to a final concentration of 10% TCA. Extracts were incubated for 15 min on ice and centrifuged at 16,100xg at 4˚C for 10 min. Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton X-100, 1% DTT. LDS loading buffer (Lifetech) was added and the pellet was heated at 70˚C for 10 min. Samples were separated on BisTris polyacrylamide gels (Lifetech) and transferred to a PVDF membrane (Lifetech). All antibodies were from Cell Signaling Technologies (Danvers, MA) except as indicated: P-STAT5 (4322), Total STAT5 (9363), P-STAT3 (9145), Total STAT3 (9139), P-ERK1/2 (4370), Total ERK1/2 (4696), P-AKT Ser473 (4060), P-AKT T308 (13038), Total AKT (4691), a-TUBULIN (3873), b-ACTIN (Santa Cruz Bioscience, Santa Cruz, CA, clone AC-17), HRP-anti-Rabbit IgG (7074) and HRP-anti-mouse IgG (7076). Blots were developed with the SuperSignal West Femto or Pico chemiluminescence kits (Thermo Scientific). Blots were stripped (1% SDS, 25 mM glycine pH 2) prior to re-probing.
Cytospins
Bone marrow cells were isolated and spun onto glass slides using a Shandon Cytospin 3. The slides were stained using Protocol Hema 3 Wright-Giemsa stain (Fisher Scientific). All slides were reviewed by a pediatric hematologist (JAM or ASC).
Statistical analysis
In all cases, multiple independent experiments were performed on at least three different days to verify that the data are reproducible. Grouped data reflect biological replicates (i.e. independent mice) and are represented by mean +/À standard deviation. Statistical comparisons between groups were made with the two-tailed Student's t-test except as noted in the figure legends. When multiple genotypes were compared, statistical significance was determined by performing a one-way ANOVA followed by a Holm-Sidak post-hoc test to correct for multiple comparisons. For transplantation experiments, the percentages of mice with multilineage reconstitution were compared with the Fisher's exact test. All comparisons were performed with GraphPad Prism 6, RRID:SCR_002798.
Gene expression analysis
Ten thousand HSCs or HPCs were double sorted directly into RLT plus RNA lysis buffer (Qiagen) and RNA was isolated with RNAeasy micro plus columns (Qiagen). Transcripts were amplified with the WTA2 kit (Sigma) with the Kreatech ULS RNA labeling kit (Kreatech Diagnostics). Labeled cDNA was hybridized to Agilent Mouse 8 Â 60 K microarrays and analyzed with an Agilent C-class scanner. Signal data were assembled and processed in Partek RRID:SCR_011860, and samples were compared by Linear Models for Microarrays, RRID:SCR_010943 (Ritchie et al., 2015; Smyth, 2004) . Adjusted p-values were calculated by the Benjamini and Hochberg false discovery rate (Benjamini and Hochberg, 1995) . Z-scores were calculated as previously described (Cheadle et al., 2003) . Hierarchical cluster analysis was performed with Cluster 3.0 and visualized with Java TreeView; RRID:SCR_013505 and RRID:SCR_013503 (Eisen et al., 1998) . Principal component analyses and Euclidean distance comparisons (by permutation testing) were performed with the R software environment. Microarray data sets have been deposited into Gene Expression Omnibus (GSE81153). GSEA was performed using gene sets that were generated as cited in the text, or with gene sets curated in the MSigDB databases; RRID:SCR_003199 (Subramanian et al., 2005) .
